retatrutide obesity clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats The data just dropped —

Characterized by intermittent hypoxia (IH), OSA is associated with increased ROS and RNS, adversely impacting cardio-/cerebro-vascular conditions in OSA patients

Moreover, the activation of E2 triggers the production of PGE2, thereby promoting the proliferation of tumors

Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Baekdal TA

Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters

H., Luque, C